Copper toxicosis in the Bedlington terrier: a diagnostic dilemma.

Diagnosis of copper toxicosis (CT) in Bedlington terriers by the quantitative and qualitative assessment of copper (Cu) in, and pathology of, biopsies has been largely superseded by a DNA-based assay which uses a microsatellite marker (C04107) linked to the CT disease allele. A retrospective study was conducted comprising 154 liver biopsies from Bedlington terriers with 22 matched DNA markers to compare the two methods in the diagnosis of CT. For the biopsy method, three categories (phenotypes) were identified based on analytical and morphological criteria: 'unaffected' in 83 samples (54 per cent), where Cu was much less than 400 microg/g, and there was an absence of visual Cu or liver damage; 'intermediate' in 18 samples (12 per cent), where Cu was less than 400 microg/g, and there was limited histochemical Cu and no/equivocal damage; and 'affected' in 53 samples (34 per cent), where Cu was greater than 400 microg/g, there was histochemical Cu and liver damage was poorly related to Cu content. In the DNA assay, which was used alone on unrelated individuals, the microsatellite marker failed to identify the CT status of any of the groups. Liver biopsy remains a reliable indicator of Cu accumulation and progressive liver disease in individual dogs. The microsatellite marker C04107 has a predictive value only when supported by a pedigree.

Digital artery calibre measurement--a new technique of assessing Raynaud's phenomenon.

This study evaluated the use of a high frequency A-mode ultrasound scanner (CUTECH DM70) for monitoring the digital artery vasospasm of Raynaud's Phenomenon (RP). The technique was evaluated on 12 RP patients and 12 age and sex matched controls. The diameter of a single digital artery was measured in these subjects over a range of finger temperatures between 14-35 degrees C. The reproducibility of the measurements was assessed by repeating the procedure in two subjects (a control and an RP patient) on 5 separate days. The results confirmed that the technique is reproducible and monitored vasospasm occurring in all 12 RP patients. In the temperature range tested, none of the controls developed digital artery vasospasm. At finger temperatures greater than 25 degrees C the response to thermal stimuli of the digital arteries in RP patients and controls was similar. However, at temperatures less than 25 degrees C a marked vasoconstriction leading to complete digital artery closure was seen in the RP patients and not in the controls. This technique may prove useful in monitoring RP patients.

Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment.

Severe renal failure is a life-threatening complication of multiple myeloma. Aggressive treatment can reverse acute renal failure in many cases but the prognosis for those who require chronic renal replacement therapy is not clear. We have reviewed the treatment of these patients in the Brighton, Dulwich and Guy's Hospitals renal units. Twenty-three patients were treated for a total of 385 months. Over half presented with end-stage renal failure and required dialysis immediately. Fifteen patients died during the study period and actuarial survival was 45 per cent at one year; six have survived for longer than two years. No prognostic features at presentation were identified but those who responded to chemotherapy survived significantly longer than those who did not. Haemodialysis and continuous ambulatory peritoneal dialysis (CAPD) appeared to be equally effective treatments. Complications from dialysis were more common than in patients with renal failure from other causes. Infection in those treated by CAPD was a serious problem and may be exacerbated by aggressive chemotherapy. Maintenance dialysis offers some patients with multiple myeloma long-term survival and should be offered to all patients who are considered to warrant continuing treatment for their underlying disease.

An epidemiological survey of Raynaud's phenomenon.

A questionnaire was sent to 1000 patients with Raynaud's phenomenon (RP) and an equal number of controls in order to accumulate one of the largest patient data banks currently available. Five-hundred and seventy-one correctly completed paired returns were processed so as to investigate the association between Raynaud's phenomenon and other factors suspected of influencing the condition. The involvement of female sex hormones in RP was indicated by the predominance of women (93%), a 6% (P less than 0.02) higher incidence of infertility and the influence of menstruation (15%), the menopause (73%) and pregnancy (53%) on symptoms. Patients with scleroderma had a 5% higher incidence of stillbirths. A familial predisposition for RP was noted dependent on age at onset of symptoms (age less than 30, 14% greater than 30, 4.9%). The Raynaud's group overall had a significantly higher percentage who had been treated for migraine (7% higher P less than 0.01), angina (3% higher P less than 0.05) and duodenal ulcer (3% higher P less than 0.001). Of the respondents who had undergone sympathectomy (n = 140, 24.5% of the total), 18.6% claimed lasting benefit and 66.4% claimed no benefit after one year. The mean age at sympathectomy was 38.6 years (S.D. +/- 13 range 14-78) with a mean age of start of symptoms of 29.2 years (S.D. +/- 14.7, range 0-70). There was no significant difference between the effects of sympathectomy on those patients with and those without associated conditions.

Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy.

Collagen is a widespread body constituent that is affected by estrogen status in women. Its decrease after menopause can be prevented and/or restored by estrogen treatment. We explored the effect of four different hormonal replacement regimens on total skin collagen content by measuring hydroxyproline in skin biopsy specimens taken from postmenopausal women. All regimens showed increases in skin collagen levels proportionate to the levels at the start of the treatment. Estrogen replacement therapy is shown to be prophylactic in women who have higher skin collagen levels and both prophylactic and therapeutic in women with lower skin collagen levels.

Acetylator phenotype in patients with lung carcinoma--a negative report.

Fractional acetylation of plasma sulphadimidine 6 h after dosing with 40 mg/kg metabolically active mass (p.o.) was measured in 53 patients with primary lung carcinoma and in 31 controls. Sixty percent of all tumour patients and 58% of controls were slow acetylators. There was no statistical evidence (P greater than 0.5) of association between acetylator phenotype and lung carcinoma.

Natural progesterone and antihypertensive action.

In a placebo controlled, double blind crossover study natural progesterone was given by mouth, in increasing doses, to six men and four postmenopausal women with mild to moderate hypertension who were not receiving any other antihypertensive drugs. When compared with values recorded before treatment and during administration of placebo progesterone caused a significant reduction in blood pressure, suggesting that progesterone has an antihypertensive action rather than a hypertensive one as has been previously thought. This possible protective effect of progesterone should be investigated further.

Peripheral vasomotor control and menopausal flushing--a preliminary report.

Menopausal flushing can be considered as an intermittent loss of peripheral vasomotor control. Thermal entrainment testing has been used to assess the degree of peripheral vasomotor control in a preliminary study of seven women receiving oestrogen replacement therapy in the form of percutaneous cream. Significant improvement was demonstrated in the degree of control over a 3-month period in those patients who were symptomatically improved. We suggest that oestrogen exerts an influence on peripheral vasomotor control and flushes and sweats occur when this influence is removed.